therapy to conventional neuroleptic treatment in schizophrenia: An open-label
study. J Neural Transm Gen Sect 95:105–111.
Castro CA, Hogan JB, Benson KA, Shehata CW and Landauer MR (1995) Behavioral
effects of vehicles: DMSO, ethanol, Tween-20, Tween-80 and emulphor-620. Pharmacol Biochem Behav 50:521–526.
Contreras PC (1990) D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology 29:291–293.
Criswell HE, Johnson KB, Mueller RA and Breese GR (1993) Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the
N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopaminelesioned rats. J Pharmacol Exp Ther 265:1001–1010.
Danysz W, Essmann U, Bresink I and Wilke R (1994) Glutamate antagonists have
different effects on spontaneous locomotor activity in rats. Pharmacol Biochem
Behav 48:111–118.
Davies SN, Martin D, Millar JD, Aram JA, Church J and Lodge D (1988) Difference
in results from in vivo and in vitro studies on the use-dependency of N- methylaspartate antagonism by MK-801 and other phencyclidine receptor ligands.
Eur J Pharmacol 145:141–151.
Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB and Morihisa JM (1989) A
“glutamatergic” hypothesis of schizophrenia. Rationale for pharmacotherapy with
glycine. Clin Neuropharmacol 12:1–13.
Ferre ́ S, Herrera-Marschitz M, Grabowska-Ande ́n M, Ungerstedt U, Casas M and
Ande ́n N-E (1991) Postsynaptic dopamine/adenosine interaction: I. Adenosine
analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized
mice. Eur J Pharmacol 192:25–30.
Fredholm BB and Dunwiddie TV (1988) How does adenosine inhibit transmitter
release? Trends Pharmacol Sci 9:130 –134.
Freed WJ, Bing LA and Wyatt RJ (1984) Effects of neuroleptics on phencyclidine
(PCP)-induced locomotor stimulation in mice. Neuropharmacology 23:175–181.
Fuxe K, Ferre ́ S, Snaprud P, von Euler G, Johansson B and Fredholm B (1993)
Antagonistic A2A/D2 receptor interactions in the striatum as a basis for adenosine/
dopamine interactions in the central nervous system. Drug Dev Res 28:374 –380.
Ginski MJ and Witkin JM (1994) Sensitive and rapid behavioral differentiation of
N-methyl-D-aspartate receptor antagonists. Psychopharmacology 114:573–582.
Glowinski J and Iversen LL (1966) Regional studies of catecholamines in the rat
brain. I: The disposition of [3H]norepinephrine, [3H]dopamine and [3H]DOPA in
various regions of the brain. J Neurochem 13:655– 669.
Goff DC, Tsai G, Manoach DS and Coyle JS (1995) Dose-finding trial of D-cycloserine
added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry
152:1213–1215.
Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I,
Murphy D and LaRue L (1995) Safety and tolerability of the glutamate antagonist
CGS 19755 (Selfotel) in patients with acute ischemic stroke. Stroke 26:602– 605.
Heffner TG, Wiley JN, Williams AE, Bruns RF, Coughenour LL and Downs DA
(1989) Comparison of the behavioral effects of adenosine agonists and dopamine
antagonists in mice. Psychopharmacology 98:31–37.
Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced
locomotion and stereotypy in rats. J Neural Transm Gen Sect 89:1–10.
Hucker HB, Hutt JE, White SD, Arison BH and Zacchei AG (1983) Disposition and
metabolism of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-5,10- imine in rats, dogs and monkeys. Drug Metab Dispos 11:54 –58.
Javitt DC, Sershen H, Hashim A and Lajtha A (1997) Reversal of phencyclidineinduced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202–204.
Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of
schizophrenia. Am J Psychiatry 148:1301–1308.
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U and Lindenmayer J-P (1994)
Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry
151:1234 –1236.
Kemp JA, Marshall GR and Priestley T (1991) A comparison of the agonistdependency of the block produced by uncompetitive NMDA receptor antagonists
on rat cortical slices. Mol Neuropharmacol 1:65–70.
Kim JS, Kornhuber HH, Schmid-Burgk W and Holzmu ̈ ller R (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci Lett 20:379 –382.
Koek W, Woods JH and Winger GD (1988) MK-801, a proposed noncompetitive
antagonist of excitatory amino acid neurotransmission, produces phencyclidinelike behavioral effects in pigeons, rats and Rhesus monkeys. J Pharmacol Exp
Ther 245:969 –974.
Korttila K and Leva ̈ nen J (1978) Untoward effects of ketamine combined with
diazepam for supplementing conduction anaesthesia in young and middle-aged
adults. Acta Anaesth Scand 22:640 – 648.
Kretschmer BD, Zadow B, Volz TL, Volz L and Schmidt WJ (1992) The contribution
of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the
expression of behavior. J Neural Transm Gen Sect 87:23–35.
Kristensen JD, Svensson B and Gordh T Jr (1992) The NMDA-receptor antagonist
CPP abolishes neurogenic “wind-up pain” after intrathecal administration in hu- mans. Pain 51:249 –253.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger
GR, Bowers MB and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199 –214.
Kuribara, H, Asami T, Ida I and Tadokoro S (1992) Characteristics of the ambulation-increasing effect of the noncompetitive NMDA antagonist MK-801 in mice:
Assessment by the coadministration with central-acting drugs. JPN J Pharmacol
58:11–18.
Kus L, Handa RJ, Hautman JM and Beitz AJ (1995) Castration increases [125]MK- 801 binding in the hippocampus of male rats. Brain Res 683:270 –274.
Larson J, Le T-T, Hall RA and Lynch G (1994) Effects of cyclothiazide on synaptic
responses in slices of adult and neonatal rat hippocampus. Neuroreport 5:389 –392.
Li X, Orwar O, Revesjo ̈ C and Sandberg M (1996) Gamma-glutamyl peptides and
